Summary
52.76 0.09(0.17%)10/15/2024
Bristol-Myers Squibb Co. (BMY)
Bristol-Myers Squibb Co. (BMY)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 0.13 | 0.53 | 5.54 | 31.42 | 8.67 | -7.71 | 15.60 | 16,360.24 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 52.76 | |
| Open | 51.31 | |
| High | 53.39 | |
| Low | 51.31 | |
| Volume | 7,931,301 | |
| Change | 0.07 | |
| Change % | 0.13 | |
| Avg Volume (20 Days) | 10,042,571 | |
| Volume/Avg Volume (20 Days) Ratio | 0.79 | |
| 52 Week Range | 39.35 - 57.65 | |
| Price vs 52 Week High | -8.48% | |
| Price vs 52 Week Low | 34.08% | |
| Range | 2.83 | |
| Gap Up/Down | -1.40 | |
Fundamentals | ||
| Market Capitalization (Mln) | 101,613 | |
| EBIDTA | 18,172,000,256 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 2.2361 | |
| WallStreet Target Price | 52.25 | |
| Book Value | 8.1350 | |
| Earnings Per Share | -3.1000 | |
| EPS Estimate Current Quarter | -4.4400 | |
| EPS Estimate Next Quarter | 1.7500 | |
| EPS Estimate Current Year | 0.5600 | |
| EPS Estimate Next Year | 6.9200 | |
| Diluted EPS (TTM) | -3.1000 | |
| Revenues | ||
| Profit Marging | -0.1350 | |
| Operating Marging (TTM) | 0.1925 | |
| Return on asset (TTM) | 0.0539 | |
| Return on equity (TTM) | -0.2533 | |
| Revenue TTM | 45,533,999,104 | |
| Revenue per share TTM | 22.2120 | |
| Quarterly Revenue Growth (YOY) | 0.0470 | |
| Quarterly Earnings Growth (YOY) | -0.0890 | |
| Gross Profit (TTM) | 36,378,000,000 | |
| Dividends | ||
| Dividend Share | 2.3400 | |
| Dividend Yield | 0.0534 | |
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 6.9300 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 3.3249 | |
| Revenue Enterprise Value | 2.8226 | |
| EBITDA Enterprise Value | 6.5597 | |
| Shares | ||
| Shares Outstanding | 2,027,100,032 | |
| Shares Float | 2,022,964,812 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.01 | |
| Insider (%) | 0.11 | |
| Institutions (%) | 80.49 | |
10/13 12:30 EST - youtube.com
3 Dividend Stocks for October 2024
#Morningstar  #VerizonStock #DividendStocks These three dividend payers have an average yield of more than 4.5%. 00:00 Introduction 00:10 Bristol-Myers Squibb BMY 00:45 Polaris PII 01:04 Verizon VZ David Harrell: Hi.
3 Dividend Stocks for October 2024
#Morningstar  #VerizonStock #DividendStocks These three dividend payers have an average yield of more than 4.5%. 00:00 Introduction 00:10 Bristol-Myers Squibb BMY 00:45 Polaris PII 01:04 Verizon VZ David Harrell: Hi.
10/11 18:51 EST - zacks.com
Bristol Myers Squibb (BMY) Stock Falls Amid Market Uptick: What Investors Need to Know
In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $52.20, denoting a -0.38% change from the preceding trading day.
Bristol Myers Squibb (BMY) Stock Falls Amid Market Uptick: What Investors Need to Know
In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $52.20, denoting a -0.38% change from the preceding trading day.
10/09 14:40 EST - zacks.com
BMY Buoyed by Recent Regulatory Updates: How to Play the Stock?
While the recent spate of positive regulatory updates boosts Bristol Myers, we will advise a wait-and-watch strategy.
BMY Buoyed by Recent Regulatory Updates: How to Play the Stock?
While the recent spate of positive regulatory updates boosts Bristol Myers, we will advise a wait-and-watch strategy.
10/09 10:08 EST - zacks.com
Is Trending Stock Bristol Myers Squibb Company (BMY) a Buy Now?
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Is Trending Stock Bristol Myers Squibb Company (BMY) a Buy Now?
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
10/06 10:30 EST - seekingalpha.com
Bristol Myers Squibb: A High-Yield Bargain With Growth On The Horizon
Frequent trading can erode gains due to transaction costs and taxes; a buy-and-hold strategy is often more effective for retail investors. Bristol Myers Squibb offers a strong dividend yield, below-average valuation, and solid growth prospects, making it a compelling buy. BMY's robust pipeline, including advancements in neurodegenerative therapies, and strong balance sheet support future growth and income potential.
Bristol Myers Squibb: A High-Yield Bargain With Growth On The Horizon
Frequent trading can erode gains due to transaction costs and taxes; a buy-and-hold strategy is often more effective for retail investors. Bristol Myers Squibb offers a strong dividend yield, below-average valuation, and solid growth prospects, making it a compelling buy. BMY's robust pipeline, including advancements in neurodegenerative therapies, and strong balance sheet support future growth and income potential.
10/03 18:51 EST - zacks.com
Bristol Myers Squibb (BMY) Advances While Market Declines: Some Information for Investors
The latest trading day saw Bristol Myers Squibb (BMY) settling at $54.20, representing a +0.82% change from its previous close.
Bristol Myers Squibb (BMY) Advances While Market Declines: Some Information for Investors
The latest trading day saw Bristol Myers Squibb (BMY) settling at $54.20, representing a +0.82% change from its previous close.
10/03 17:35 EST - businesswire.com
U.S. Food and Drug Administration Approves Perioperative Treatment of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable Non-Small Cell Lung Cancer (NSCLC)
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CheckMate--U.S. FDA Approves Perioperative Treatment of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo.
U.S. Food and Drug Administration Approves Perioperative Treatment of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable Non-Small Cell Lung Cancer (NSCLC)
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CheckMate--U.S. FDA Approves Perioperative Treatment of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo.
10/03 06:45 EST - fool.com
2 Passive-Income Stocks to Load Up On in October
These two dividend powerhouses are ideal choices for passive-income investors.
2 Passive-Income Stocks to Load Up On in October
These two dividend powerhouses are ideal choices for passive-income investors.
09/30 13:43 EST - reuters.com
Bristol Myers beats $6.4 billion lawsuit over delayed cancer drug
Bristol Myers Squibb won the dismissal on Monday of a $6.4 billion lawsuit claiming it cheated former Celgene shareholders by delaying federal approval for the cancer drug Breyanzi and two other drugs developed by Celgene.
Bristol Myers beats $6.4 billion lawsuit over delayed cancer drug
Bristol Myers Squibb won the dismissal on Monday of a $6.4 billion lawsuit claiming it cheated former Celgene shareholders by delaying federal approval for the cancer drug Breyanzi and two other drugs developed by Celgene.
09/30 08:38 EST - benzinga.com
Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline
On Monday, Prime Medicine Inc. PRME announced a strategic research collaboration and license agreement with Bristol Myers Squibb & Co BMY to develop reagents for the next generation of ex vivo T-cell therapies.
Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline
On Monday, Prime Medicine Inc. PRME announced a strategic research collaboration and license agreement with Bristol Myers Squibb & Co BMY to develop reagents for the next generation of ex vivo T-cell therapies.
09/28 07:30 EST - fool.com
3 Surprisingly Underrated Stocks to Buy Right Now
Bristol Myers Squibb is trading at a significant discount. Moderna has a lot of irons in the fire.
3 Surprisingly Underrated Stocks to Buy Right Now
Bristol Myers Squibb is trading at a significant discount. Moderna has a lot of irons in the fire.
09/28 01:04 EST - seekingalpha.com
Bristol-Myers Squibb Likely To Revalue Higher Following New Drug Approval
Bristol-Myers Squibb's stock is poised to rise due to the FDA approval of Cobenfy, a novel antipsychotic for schizophrenia, and improved technicals. The company's $14 billion acquisition of Karuna Therapeutics and subsequent drug approval validates the investment and supports a higher stock price. BMY's strong oncology portfolio, including Opdivo and Revlimid, and recent acquisitions bolster its fundamentals, targeting a price range of $59.50 to $61.60.
Bristol-Myers Squibb Likely To Revalue Higher Following New Drug Approval
Bristol-Myers Squibb's stock is poised to rise due to the FDA approval of Cobenfy, a novel antipsychotic for schizophrenia, and improved technicals. The company's $14 billion acquisition of Karuna Therapeutics and subsequent drug approval validates the investment and supports a higher stock price. BMY's strong oncology portfolio, including Opdivo and Revlimid, and recent acquisitions bolster its fundamentals, targeting a price range of $59.50 to $61.60.
09/27 18:00 EST - youtube.com
Bristol Myers Squibb stock rises following FDA approval of its schizophrenia drug
CNBC's Angelica Peebles joins 'Fast Money' to report on Bristol Myers Squibb's stock rise following FDA approval of Cobenfy for treating schizophrenia in adults.
Bristol Myers Squibb stock rises following FDA approval of its schizophrenia drug
CNBC's Angelica Peebles joins 'Fast Money' to report on Bristol Myers Squibb's stock rise following FDA approval of Cobenfy for treating schizophrenia in adults.
09/27 15:06 EST - benzinga.com
Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential
On Thursday, the FDA approved Bristol Myers Squibb & Co's BMY Cobenfy (xanomeline and trospium chloride, KarXT), an oral medication for schizophrenia in adults.
Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential
On Thursday, the FDA approved Bristol Myers Squibb & Co's BMY Cobenfy (xanomeline and trospium chloride, KarXT), an oral medication for schizophrenia in adults.
09/27 11:45 EST - seekingalpha.com
Bristol-Myers Squibb: Cobenfy Approval A Major Coup For The Dealmaker (Upgrade)
Bristol-Myers Squibb's acquisition of Karuna for $14bn and the subsequent FDA approval of Cobenfy, a novel schizophrenia drug, represents a significant strategic win. Cobenfy, the first new schizophrenia treatment in 35 years, has peak sales potential estimated at $7.5bn, validating Bristol-Myers' investment and boosting its market position. Despite recent financial struggles and high debt, Bristol-Myers' robust pipeline and strategic acquisitions position it for substantial revenue growth by 2030.
Bristol-Myers Squibb: Cobenfy Approval A Major Coup For The Dealmaker (Upgrade)
Bristol-Myers Squibb's acquisition of Karuna for $14bn and the subsequent FDA approval of Cobenfy, a novel schizophrenia drug, represents a significant strategic win. Cobenfy, the first new schizophrenia treatment in 35 years, has peak sales potential estimated at $7.5bn, validating Bristol-Myers' investment and boosting its market position. Despite recent financial struggles and high debt, Bristol-Myers' robust pipeline and strategic acquisitions position it for substantial revenue growth by 2030.
09/27 11:43 EST - schaeffersresearch.com
Pharma Stock Rises on Cleared Schizophrenia Treatment
Bristol-Myers Squibb Co (NYSE:BMY) is up 3.2% at $51.71, after the U.S. Food & Drug Administration (FDA) approved the pharma name's schizophrenia treatment, Cobenfy.
Pharma Stock Rises on Cleared Schizophrenia Treatment
Bristol-Myers Squibb Co (NYSE:BMY) is up 3.2% at $51.71, after the U.S. Food & Drug Administration (FDA) approved the pharma name's schizophrenia treatment, Cobenfy.
09/27 11:06 EST - businesswire.com
Bristol Myers Squibb Presents New Data from Two Trials Demonstrating Sotyktu (deucravacitinib) Efficacy in both Moderate-to-Severe Scalp Psoriasis and in a Real-World Setting
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #PSORIATYK--BMS Presents New Data from Two Trials Demonstrating Sotyktu Efficacy in both Moderate-to-Severe Scalp Psoriasis and in a Real-World Setting.
Bristol Myers Squibb Presents New Data from Two Trials Demonstrating Sotyktu (deucravacitinib) Efficacy in both Moderate-to-Severe Scalp Psoriasis and in a Real-World Setting
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #PSORIATYK--BMS Presents New Data from Two Trials Demonstrating Sotyktu Efficacy in both Moderate-to-Severe Scalp Psoriasis and in a Real-World Setting.
09/27 11:05 EST - zacks.com
Bristol Myers Stock Up on FDA Nod for Schizophrenia Treatment
The FDA approves BMY's differentiated schizophrenia treatment for adults and broadens its diverse portfolio. Shares gain.
Bristol Myers Stock Up on FDA Nod for Schizophrenia Treatment
The FDA approves BMY's differentiated schizophrenia treatment for adults and broadens its diverse portfolio. Shares gain.
09/27 10:18 EST - investopedia.com
Bristol Myers Squibb Stock Rises After Schizophrenia Drug Gets FDA Approval
Shares of Bristol Myers Squibb (BMY) rose Friday, a day after the Food and Drug Administration (FDA) approved the use of what the pharmaceutical firm called the first treatment for schizophrenia in decades.
Bristol Myers Squibb Stock Rises After Schizophrenia Drug Gets FDA Approval
Shares of Bristol Myers Squibb (BMY) rose Friday, a day after the Food and Drug Administration (FDA) approved the use of what the pharmaceutical firm called the first treatment for schizophrenia in decades.
09/27 10:06 EST - youtube.com
COST Earnings Slip, BMY Schizophrenia Drug Approval, HPQ Downgrade
Costco (COST), one of the biggest names in retail, slips after earnings. Despite a beat on the top line and membership fees, revenue and comp.
COST Earnings Slip, BMY Schizophrenia Drug Approval, HPQ Downgrade
Costco (COST), one of the biggest names in retail, slips after earnings. Despite a beat on the top line and membership fees, revenue and comp.